- Home
- ENSC vs ACON Comparison
ENSC vs ACON Comparison
Compare ENSC & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- ACON
- Stock Information
- Founded
- ENSC 2003
- ACON 2008
- Country
- ENSC United States
- ACON United States
- Employees
- ENSC N/A
- ACON N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- ENSC Health Care
- ACON Technology
- Exchange
- ENSC Nasdaq
- ACON Nasdaq
- Market Cap
- ENSC 4.9M
- ACON 4.2M
- IPO Year
- ENSC N/A
- ACON 2022
- Fundamental
- Price
- ENSC $2.22
- ACON $7.28
- Analyst Decision
- ENSC
- ACON Buy
- Analyst Count
- ENSC 0
- ACON 2
- Target Price
- ENSC N/A
- ACON $481.00
- AVG Volume (30 Days)
- ENSC 230.3K
- ACON 15.5K
- Earning Date
- ENSC 08-13-2025
- ACON 08-13-2025
- Dividend Yield
- ENSC N/A
- ACON N/A
- EPS Growth
- ENSC N/A
- ACON N/A
- EPS
- ENSC N/A
- ACON N/A
- Revenue
- ENSC $6,224,081.00
- ACON $54,601.00
- Revenue This Year
- ENSC N/A
- ACON $212.31
- Revenue Next Year
- ENSC $1,381.48
- ACON $92.86
- P/E Ratio
- ENSC N/A
- ACON N/A
- Revenue Growth
- ENSC 256.35
- ACON N/A
- 52 Week Low
- ENSC $1.62
- ACON $6.20
- 52 Week High
- ENSC $14.67
- ACON $3,499.51
- Technical
- Relative Strength Index (RSI)
- ENSC 49.53
- ACON 42.96
- Support Level
- ENSC $2.02
- ACON $6.79
- Resistance Level
- ENSC $2.30
- ACON $7.29
- Average True Range (ATR)
- ENSC 0.14
- ACON 0.37
- MACD
- ENSC 0.02
- ACON 0.31
- Stochastic Oscillator
- ENSC 43.40
- ACON 45.79
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.